Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

U.S. development Phase success rates for rare and common disease drugs 2006-2015

This statistic shows the probability of success for new rare disease and high prevalence disease drugs in the U.S. through the various stages of development, from January 1, 2006 to December 31, 2015. It was found that while the probability that a new drug for a chronic high prevalence disease makes it from Phase I to approval was only 8.7 percent, it was 25.3 percent for rare disease drugs.

Probability of success for new rare disease and high prevalence disease drugs in the U.S. by development phase from 2006 to 2015

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until March 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

May 2016

Region

United States

Survey time period

January 1, 2006 to December 31, 2015

Supplementary notes

* NDA - New Drug Application / BLA - Biologic License Application.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Orphan drugs"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.